RECRUITING

LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions

Description

To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).

Study Overview

Study Details

Study overview

To establish the effectiveness and tolerability of standard of care anti-anginal treatment (beta-blocker and calcium channel blocker medications) in older adults with symptomatic Stable Ischemic Heart Disease (SIHD) and multiple chronic conditions (MCC).

A Trial Comparing the Effectiveness and Tolerability of Medications in Older Adults With Stable Angina and Multiple Chronic Conditions: LIVEBETTER

LIVEBETTER: A Trial Comparing Medications in Older Adults With Stable Angina and Multiple Chronic Conditions

Condition
Angina
Intervention / Treatment

-

Contacts and Locations

New Haven

Yale School of Medicine, New Haven, Connecticut, United States, 06520

Marietta

Wellstar Research Institute, Marietta, Georgia, United States, 30060

Chicago

Cook County Health, Chicago, Illinois, United States, 60612

Boston

Brigham and Women's Hospital, Boston, Massachusetts, United States, 02115

New York

Mt. Sinai Health System, New York, New York, United States, 10029

New York

NYC Health and Hospitals, Harlem Hospital, New York, New York, United States, 10037-1802

New York

Nirvana Integrative Medicine, New York, New York, United States, 10469

Durham

Duke University, School of Medicine, Durham, North Carolina, United States, 27710

Fairfax

Inova Health Care Services, Fairfax, Virginia, United States, 22033

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥70 years; ≥65 years for underrepresented minorities (URM) of black race or Hispanic ethnicity
  • * ≥ 2 Multiple Chronic Conditions as defined by Centers for Medicare and Medicaid Services (CMS)
  • * Diagnosis of Symptomatic Stable Ischemic Heart Disease with plans to initiate medical therapy identified by at least one of the following:
  • 1. positive non-invasive functional or anatomic testing suggestive of obstructive coronary artery disease
  • 2. coronary angiography with stenosis ≥70% in a coronary artery ≥2 mm in diameter or
  • 3. Invasive coronary angiography with positive physiologic testing in at least one vessel (FFR ≤ 0.80 or iFR ≤0.89)
  • * Age ≥ 18 years
  • * Identified as caregiver of LIVEBETTER participant
  • * Current taking beta-blocker or calcium channel blocker\*
  • * Contraindication to beta-blockers or calcium channel blockers including:
  • 1. significant hypotension
  • 2. high grade AV block
  • 3. severe symptomatic bradycardia
  • 4. severe obstructive lung disease
  • * Documented intolerance to beta-blockers or calcium channel blockers
  • * Probable or definite high-risk coronary artery disease including unrevascularized left main disease and/or unrevascularized multi-vessel disease including the proximal left anterior descending (LAD) artery with plans for immediate complete revascularization
  • * Plans for complete revascularization within 2 weeks
  • * Clear indication for beta-blockers or calcium channel blockers including:
  • 1. Diagnosis of acute coronary syndrome (ACS) with reduced ejection fraction within past year
  • 2. Heart failure with reduced ejection fraction (HFrEF) within past year
  • * Actively participating in another clinical trial involving an investigational medication or device
  • * Primary language other than English or Spanish
  • * Inability to complete follow-up (e.g. life expectancy \<12 months, impaired decision-making determined by validated instrument)
  • * Previously enrolled in LIVEBETTER
  • * Refused informed consent
  • * Professional caregiver (i.e. not a relative or close friend of the participant)
  • * Primary language other than English or Spanish
  • * Inability to complete follow-up
  • * Previously enrolled in LIVEBETTER
  • * Refused informed consent

Ages Eligible for Study

65 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Yale University,

Michael Nanna, MD, PRINCIPAL_INVESTIGATOR, Yale University

Study Record Dates

2027-05-30